55
Participants
Start Date
June 1, 2021
Primary Completion Date
January 31, 2023
Study Completion Date
August 31, 2023
MBM-02
Study drug will be administered orally using the capsule formulation (200 mg). The study drug will be administered 7 days a week for the entire treatment period.
Georgetown, Washington D.C.
Lead Sponsor
Collaborators (1)
MedStar Health
OTHER
Matrix Biomed, Inc.
INDUSTRY